{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:30:23Z","timestamp":1786563023302,"version":"build-2736575974"},"publisher-location":"Berlin, Heidelberg","reference-count":58,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_826","type":"book-chapter","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:58:28Z","timestamp":1786561108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Tolerability of SGLT2 Inhibitors"],"prefix":"10.1007","author":[{"given":"Marcel H. A.","family":"Muskiet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl H.","family":"van Raalte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"826_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajmo.2025.100115","volume":"14","author":"B Admani","year":"2025","unstructured":"Admani B, Raza FZ, Siddiqui F, Ashraf MT, Khan MK, Habib I et al (2025) The impact of different antidiabetic drugs on fracture risk in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized controlled trials with a focus on SGLT2 inhibitors. Am J Med Open 14:100115","journal-title":"Am J Med Open"},{"issue":"16","key":"826_CR2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"1","key":"826_CR3","doi-asserted-by":"crossref","first-page":"10293","DOI":"10.1038\/s41598-021-89752-w","volume":"11","author":"F Ata","year":"2021","unstructured":"Ata F, Yousaf Z, Khan AA, Razok A, Akram J, Ali EAH et al (2021) SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep 11(1):10293","journal-title":"Sci Rep"},{"issue":"5","key":"826_CR4","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.numecd.2021.02.006","volume":"31","author":"Y Bai","year":"2021","unstructured":"Bai Y, Jin J, Zhou W, Zhang S, Xu J (2021) The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 31(5):1365\u20131374","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"826_CR5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK et al (2021a) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384(2):129\u2013139","journal-title":"N Engl J Med"},{"issue":"2","key":"826_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al (2021b) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117\u2013128","journal-title":"N Engl J Med"},{"issue":"1","key":"826_CR7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D et al (2016) Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101(1):44\u201351","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"826_CR8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","volume":"14","author":"JE Blau","year":"2018","unstructured":"Blau JE, Taylor SI (2018) Adverse effects of SGLT2 inhibitors on bone health. Nat Rev Nephrol 14(8):473\u2013474","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"826_CR9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","volume":"16","author":"J Bolinder","year":"2014","unstructured":"Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD et al (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16(2):159\u2013169","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"826_CR10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425\u20131435","journal-title":"N Engl J Med"},{"issue":"5","key":"826_CR11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587\u2013597","journal-title":"Circulation"},{"issue":"6","key":"826_CR12","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42(6):1147\u20131154","journal-title":"Diabetes Care"},{"issue":"3","key":"826_CR13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/dom.14271","volume":"23","author":"T Danne","year":"2021","unstructured":"Danne T, Edelman S, Frias JP, Ampudia-Blasco FJ, Banks P, Jiang W et al (2021) Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index >\/= 27 kg\/m(2). Diabetes Obes Metab 23(3):854\u2013860","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"826_CR14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","volume":"40","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Barsotti E, Clerico A et al (2017) Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 40(6):771\u2013776","journal-title":"Diabetes Care"},{"key":"826_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/FJC.0000000000001703","volume":"86","author":"KJ Galli","year":"2025","unstructured":"Galli KJ, Wadid M, Bessada Y (2025) Sodium-glucose transporter-2 inhibitors: safety and efficacy in patients with peripheral artery disease. J Cardiovasc Pharmacol 86:19","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"826_CR16","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/dom.13754","volume":"21","author":"RE Gilbert","year":"2019","unstructured":"Gilbert RE, Thorpe KE (2019) Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab 21(8):1996\u20132000","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"826_CR17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"6","key":"826_CR18","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/dom.15571","volume":"26","author":"A Hodgson","year":"2024","unstructured":"Hodgson A, Gillies CL, Highton P, Haddon L, Gharibzadeh S, Zaccardi F et al (2024) Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: a systematic review and meta-analysis of observational cohort studies. Diabetes Obes Metab 26(6):2487\u20132491","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"826_CR19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14740338.2020.1694659","volume":"19","author":"K Kaku","year":"2020","unstructured":"Kaku K, Chin R, Naito Y, Iliev H, Ikeda R, Ochiai K et al (2020) Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study. Expert Opin Drug Saf 19(2):211\u2013221","journal-title":"Expert Opin Drug Saf"},{"issue":"16","key":"826_CR20","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","volume":"83","author":"V Kittipibul","year":"2024","unstructured":"Kittipibul V, Cox ZL, Chesdachai S, Fiuzat M, Lindenfeld J, Mentz RJ (2024) Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week. J Am Coll Cardiol 83(16):1568\u20131578","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"826_CR21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85(4):962\u2013971","journal-title":"Kidney Int"},{"issue":"7","key":"826_CR22","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","volume":"34","author":"S Kohler","year":"2017","unstructured":"Kohler S, Zeller C, Iliev H, Kaspers S (2017) Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther 34(7):1707\u20131726","journal-title":"Adv Ther"},{"issue":"4","key":"826_CR23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.34067\/KID.0000412021","volume":"2","author":"D Lam","year":"2021","unstructured":"Lam D, Shaikh A (2021) Real-life prescribing of SGLT2 inhibitors: how to handle the other medications, including glucose-lowering drugs and diuretics. Kidney360 2(4):742\u2013746","journal-title":"Kidney360"},{"issue":"2","key":"826_CR24","first-page":"10","volume":"12","author":"GI Lambrou","year":"2025","unstructured":"Lambrou GI, Samartzi A, Vlachou E, Tsartsalis AN (2025) Is the impact of sodium-glucose co-transporter 2 (SGLT2) inhibitors on bone metabolism and fracture incidence a class or drug effect? A Narrative review. Medicines (Basel) 12(2):10","journal-title":"Medicines (Basel)"},{"issue":"12","key":"826_CR25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41574-025-01170-4","volume":"21","author":"YH Lee","year":"2025","unstructured":"Lee YH, Lim S, Davies MJ (2025) Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 inhibitors. Nat Rev Endocrinol 21(12):783\u2013798","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"826_CR26","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","volume":"14","author":"O Ljunggren","year":"2012","unstructured":"Ljunggren O, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjostrom CD et al (2012) Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 14(11):990\u2013999","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"826_CR27","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Y Lytvyn","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI (2017) Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136(17):1643\u20131658","journal-title":"Circulation"},{"issue":"21","key":"826_CR28","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"key":"826_CR29","doi-asserted-by":"crossref","unstructured":"Nani A, Carrara F, Paulesu CME, Dalle Fratte C, Padroni M, Enisci S et al (2023) Association of Sodium-Glucose Cotransporter 2 Inhibitors with osteomyelitis and other lower limb safety outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. J Clin Med 12(12)","DOI":"10.3390\/jcm12123958"},{"key":"826_CR30","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1111\/dom.70520","volume":"28","author":"M Nardone","year":"2026","unstructured":"Nardone M, Moedt E, Heerspink HJL, Davies MJ, Girard M, Cherney DZI et al (2026) Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: a biomarker analysis of the inTandem3 clinical trial. Diabetes Obes Metab 28:3254","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"826_CR31","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE et al (2019) Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 140(18):1463\u20131476","journal-title":"Circulation"},{"issue":"7","key":"826_CR32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"10365","key":"826_CR33","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788\u20131801","journal-title":"Lancet"},{"issue":"7","key":"826_CR34","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1111\/dom.16385","volume":"27","author":"DV O'Hara","year":"2025","unstructured":"O'Hara DV, Jardine MJ (2025) A review of the safety of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab 27(7):3598\u20133606","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"826_CR35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"24","key":"826_CR36","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306","journal-title":"N Engl J Med"},{"issue":"5","key":"826_CR37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB (2018) SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55(5):503\u2013514","journal-title":"Acta Diabetol"},{"key":"826_CR38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","volume":"140","author":"K Radholm","year":"2018","unstructured":"Radholm K, Wu JH, Wong MG, Foote C, Fulcher G, Mahaffey KW et al (2018) Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - a systematic review. Diabetes Res Clin Pract 140:118\u2013128","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"826_CR39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/dom.13103","volume":"20","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Frias J, Pall D, Charbonnel B, Pascu R, Saur D et al (2018) Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 20(3):520\u2013529","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"826_CR40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","volume":"44","author":"RA Scholtes","year":"2021","unstructured":"Scholtes RA, Muskiet MHA, van Baar MJB, Hesp AC, Greasley PJ, Karlsson C et al (2021) Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care 44(2):440\u2013447","journal-title":"Diabetes Care"},{"issue":"24","key":"826_CR41","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/CIRCULATIONAHA.122.061033","volume":"146","author":"RA Scholtes","year":"2022","unstructured":"Scholtes RA, Hesp AC, Mosterd CM, Geurts F, Hoorn EJ, Touw DJ et al (2022) Kidney hemodynamic effects of angiotensin receptor blockade, sodium-glucose cotransporter-2 inhibition alone, and their combination: a crossover randomized trial in people with type 2 diabetes. Circulation 146(24):1895\u20131897","journal-title":"Circulation"},{"key":"826_CR42","volume":"103","author":"LIP Snel","year":"2025","unstructured":"Snel LIP, Oosterom-Eijmael MJP, Rampanelli E, Lankadeva YR, Plummer MP, Preckel B et al (2025) The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: an open-label randomized pilot study. J Clin Anesth 103:111811","journal-title":"J Clin Anesth"},{"issue":"4","key":"826_CR43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","volume":"76","author":"VS Sridhar","year":"2020","unstructured":"Sridhar VS, Tuttle KR, Cherney DZI (2020) We can finally stop worrying about SGLT2 inhibitors and acute kidney injury. Am J Kidney Dis 76(4):454\u2013456","journal-title":"Am J Kidney Dis"},{"key":"826_CR44","doi-asserted-by":"crossref","unstructured":"Sridharan K, Sivaramakrishnan G (2024) Risk of diabetic ketoacidosis associated with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. J Clin Med 13(6)","DOI":"10.3390\/jcm13061748"},{"issue":"8","key":"826_CR45","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI (2015a) SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100(8):2849\u20132852","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"826_CR46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","volume":"3","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI (2015b) Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3(1):8\u201310","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"826_CR47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127","journal-title":"N Engl J Med"},{"issue":"4","key":"826_CR48","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","volume":"28","author":"L Tonneijck","year":"2017","unstructured":"Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH et al (2017) Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28(4):1023\u20131039","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"826_CR49","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","volume":"137","author":"JA Udell","year":"2018","unstructured":"Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N (2018) Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation 137(14):1450\u20131459","journal-title":"Circulation"},{"issue":"1","key":"826_CR50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/jdi.13097","volume":"11","author":"K Utsunomiya","year":"2020","unstructured":"Utsunomiya K, Senda M, Kakiuchi S, Kameda H, Tamura M, Kurihara Y et al (2020) Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP\/LT). J Diabetes Investig 11(1):132\u2013141","journal-title":"J Diabetes Investig"},{"issue":"11","key":"826_CR51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon V (2024) State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens 37(11):841\u2013852","journal-title":"Am J Hypertens"},{"issue":"23","key":"826_CR52","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1042\/CS20201274","volume":"134","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Geurts F, Muskiet MHA, Post A, Bakker SJL, Danser AHJ et al (2020a) SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: tubular effects of SGLT2 inhibition in type 2 diabetes. Clin Sci (Lond) 134(23):3107\u20133118","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"826_CR53","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL et al (2020b) The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 97(1):202\u2013212","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"826_CR54","doi-asserted-by":"crossref","first-page":"i24","DOI":"10.1093\/ndt\/gfz228","volume":"35","author":"DH van Raalte","year":"2020","unstructured":"van Raalte DH, Bjornstad P (2020) Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes. Nephrol Dial Transplant 35(Suppl 1):i24\u2013i32","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"826_CR55","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/ejhf.2584","volume":"24","author":"D Vukadinovic","year":"2022","unstructured":"Vukadinovic D, Abdin A, Anker SD, Rosano GMC, Mahfoud F, Packer M et al (2022) Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. Eur J Heart Fail 24(9):1625\u20131632","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"826_CR56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357","journal-title":"N Engl J Med"},{"issue":"10","key":"826_CR57","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00125-019-4955-5","volume":"62","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D et al (2019) Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS program. Diabetologia 62(10):1854\u20131867","journal-title":"Diabetologia"},{"issue":"22","key":"826_CR58","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:58:36Z","timestamp":1786561116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":58,"URL":"https:\/\/doi.org\/10.1007\/164_2026_826","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"13 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}